Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Yu. Yu. Polyakov"'
Autor:
Yu. Yu. Polyakov, E. A. Baryakh, E. N. Misyurina, E. I. Zhelnova, M. A. Mingalimov, S. A. Kardovskaya, M. Ya. Smolyarchuk, T. N. Tolstykh, T. S. Chudnova, D. D. Ivanova, O. L. Kochneva, D. V. Lebedev, A. U. Abueva, A. M. Chistov, E. N. Zotina, I. V. Samsonova, M. A. Lysenko
Publikováno v:
Онкогематология, Vol 19, Iss 2, Pp 101-108 (2024)
Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to
Externí odkaz:
https://doaj.org/article/6ad4e363aae34c35b0a8dbd147ff46eb
Autor:
M. A. Mingalimov, E. A. Baryakh, O. L. Kochneva, E. N. Misyurina, Yu. Yu. Polyakov, E. I. Zhelnova, K. V. Yatskov, A. B. Makeshova, T. N. Tolstykh, T. S. Chudnova, D. D. Ivanova, D. V. Lebedev, E. N. Zotina, D. E. Gagloeva, M. M. Beregov, E. A. Mamatturdiev, I. V. Samsonova, M. A. Lysenko
Publikováno v:
Онкогематология, Vol 19, Iss 2, Pp 75-82 (2024)
Diffuse large B-cell lymphoma is the most common immunomorphological variant of lymphoma in adults. Extranodal lesions are observed in a third of patients at the disease onset. The organs most often involved are the gastrointestinal tract, testicles,
Externí odkaz:
https://doaj.org/article/778f7ec549ee43658eeee7c8bd204bc8
Autor:
V. N. Yakimets, E. N. Misyurina, E. I. Zhelnova, E. A. Baryakh, K. V. Yatskov, A. B. Makeshova, E. A. Karimova, E. N. Zotina, E. Yu. Grishina, D. E. Gagloeva, M. A. Mingalimov, T. N. Tolstykh, T. S. Chudnova, O. L. Kochneva, L. T. Shimanovskaya, Yu. Yu. Polyakov
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 86-90 (2024)
Background. In March 2020, doctors faced the problem of severe COVID-19 coronavirus infection in patients with multiple myeloma. This required a review of issues related to the selection of patients, the development of new preventive and therapeutic
Externí odkaz:
https://doaj.org/article/16908b3edb5e4d8f90a42e770c340559
Autor:
O. L. Kochneva, E. A. Baryakh, E. N. Misyurina, E. I. Zhelnova, K. V. Yatskov, T. S. Chudnova, Yu. Yu. Polyakov, A. B. Makeshova, M. A. Mingalimov, D. D. Ivanova, L. T. Shimanovskaya, E. N. Zotina, T. N. Tolstykh, E. Yu. Grishina, D. E. Gagloeva, V. N. Yakimets, A. I. Koneva, E. A. Karimova
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 64-73 (2024)
Background. At the end of 2019, a new coronavirus infection caused by the SARS-CoV-2 virus was registered. In March 2020, the first cases of COVID-19 were detected in Moscow. Patients with chronic lymphocytic leukemia, characterized by profound immun
Externí odkaz:
https://doaj.org/article/28110400142b4f29a4bdd886c5d5d04d
Autor:
T. S. Chudnova, E. N. Misyurina, E. A. Baryakh, T. N. Tolstykh, L. T. Shimanovskaya, D. E. Gagloeva, E. I. Zhelnova, A. B. Makeshova, K. V. Yatskov, E. N. Zotina, D. D. Ivanova, M. A. Mingalimov, O. L. Kochneva, E. Yu. Grishina, Yu. Yu. Polyakov, V. N. Yakimets
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 45-52 (2024)
Patients with acute leukemia are one of the most vulnerable risk groups for infection with SARS-CoV-2 and severe course of coronavirus infection. During the first 2 years of the pandemic, the mortality rate of patients with acute leukemia was 11-48 %
Externí odkaz:
https://doaj.org/article/562373b3d4a34ce08d461076cd4f6999
Autor:
E. N. Misyurina, E. A. Baryakh, N. F. Frolova, O. N. Kotenko, Z. Yu. Mutovina, S. S. Andreev, T. N. Tolstykh, K. V. Yatskov, E. A. Karimova, A. B. Makeshova, O. A. Rukavitsyn, A. V. Misyurin, Yu. Yu. Polyakov, M. A. Mingalimov, T. S. Chudnova, D. E. Gagloeva, D. D. Ivanova, A. I. Koneva, O. L. Kochneva, E. N. Zotina, E. Yu. Grishina, L. T. Shimanovskaya, V. N. Yakimets, E. I. Zhelnova
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 10-39 (2024)
In December 2019, cases of severe respiratory infection were reported in Wuhan, China. The disease was caused by a new, previously undescribed coronavirus, structurally similar to the then known SARS-CoV virus. The World Health Organization has named
Externí odkaz:
https://doaj.org/article/6c9982b78af94d8e92e3fb3b76bf0c82
Autor:
Yu. Yu. Polyakov, E. A. Baryakh, E. N. Misyurina, E. I. Zhelnova, K. V. Yatskov, A. B. Makeshova, M. A. Mingalimov, T. N. Tolstykh, T. S. Chudnova, D. D. Ivanova, A. I. Koneva, O. L. Kochneva, E. N. Zotina, D. E. Gagloeva, E. Yu. Grishina, L. T. Shimanovskaya, V. N. Yakimets
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 74-85 (2024)
Background. Coronavirus disease (COVID-19), caused by SARS-CoV-2, presents new challenges to hematologists, highlighting the vulnerability of patients with hematological malignancies, in particular with diffuse large B-cell lymphoma (DLBCL). Identifi
Externí odkaz:
https://doaj.org/article/6d577e6096394b05aacb0118ea2f445b
Autor:
E. Yu. Grishina, E. N. Misyurina, E. I. Zhelnova, E. A. Baryakh, K. V. Yatskov, A. B. Makeshova, E. A. Karimova, E. N. Zotina, D. E. Gagloeva, V. N. Yakimets, M. A. Mingalimov, T. N. Tolstykh, Yu. Yu. Polyakov, T. S. Chudnova, O. L. Kochneva, L. T. Shimanovskaya
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 91-95 (2024)
Background. In March 2020, oncohematologists faced the problem of severe COVID-19 coronavirus infection in patients after a high-dose chemotherapy and autologous or allogeneic bone marrow transplantation. This required a review of issues related to t
Externí odkaz:
https://doaj.org/article/ca3560c4cb4a49428d290e92bb3a4258
Autor:
L. T. Shimanovskaya, E. N. Misyurina, E. A. Baryakh, E. I. Zhelnova, K. V. Yatskov, T. S. Chudnova, A. B. Makeshova, M. A. Mingalimov, D. D. Ivanova, O. L. Kochneva, E. N. Zotina, T. N. Tolstykh, E. Yu. Grishina, D. E. Gagloeva, Yu. Yu. Polyakov, V. N. Yakimets, A. I. Koneva
Publikováno v:
Онкогематология, Vol 18, Iss 4, Pp 53-63 (2024)
Aim. To study the course of COVID-19 (COronaVIrus Disease 2019) in elderly patients with acute myeloid leukemia (AML), to analyze risk factors for unfavorable outcome.Materials and methods. The paper presents our own experience in the treatment of el
Externí odkaz:
https://doaj.org/article/fa10cb71761a4699b81be67c9d740c42
Autor:
E. S. Nesterova, S. K. Kravchenko, A. M. Kovrigina, E. G. Gemdzhian, L. V. Plastinina, Ya. K. Mangasarova, F. E. Babaeva, A. E. Misyurina, O. V. Margolin, A. U. Magomedova, V. I. Vorobiev, D. S. Maryin, E. A. Baryakh, Yu. Yu. Polyakov, P. A. Zeynalova, E. M. Volodicheva, N. N. Glonina, N. V. Minaeva, G. A. Davydova, V. G. Savchenko
Publikováno v:
Онкогематология, Vol 13, Iss 3, Pp 10-24 (2018)
Background. Follicular lymphoma (FL) is the most common type of indolent lymphomas and accounts for 20–30 % of all non-Hodgkin’s lymphomas detected. High risk of recurrence and elderly patients make it difficult to choose induction therapy for FL
Externí odkaz:
https://doaj.org/article/cf0dfc1037f240a49382053175c77ec2